Xconomy | Boston - Business + Technology in the Exponential Economy

Biotech, deals, Life Sciences

Alseres Raises $5 Million From Former Director, Robert Gipson

Luke Timmerman 6/30/08

Alseres Pharmaceuticals, (NASDAQ: ALSE) a developer of neurological drugs and diagnostics, said today it raised $5 million in convertible debt from Robert Gipson, a General Partner of Ingalls & Snyder Value Partners, and a former director of the company. Gipson can convert the loan principal into shares of the company’s stock at $2.50 a share. The Hopkinton, MA-based company’s shares climbed 4 cents to $2.34 at 1:34 p.m. Eastern time today, following the announcement.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.


Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.